Xultophy Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Xultophy Injection is a combination of two medicines, liraglutide and insulin degludec. Its labelling describes it for the treatment of type 2 diabetes mellitus, injected under the skin when blood sugar levels are not controlled even after using other medications, and used together with diet and exercise. Liraglutide is described as making more insulin during meals and lowering the sugar level, while insulin degludec mimics the body’s natural insulin; together they control blood sugar throughout the day and reduce the risk of serious diabetes complications.
Product Information
The following description reflects information associated with this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of type 2 diabetes mellitus
- Described as used when blood sugar is not controlled even after other medications, together with diet and exercise
- Described as lowering blood glucose levels and keeping them in control, reducing the risk of serious diabetes complications
Described Dosage & Administration
- Given by a professional doctor or nurse; if the patient is advised to self-inject, the correct technique should be learned from them
- Injected under the skin, used regularly at the dose and duration prescribed by the doctor
- It should not be stopped midway, as that can raise blood sugar levels
Described Side Effects
Commonly described side effects include:
- Headache
- Nausea and vomiting
- Diarrhoea
- Hypoglycaemia (low blood glucose level)
- Decreased appetite
- Upper respiratory tract infection and sore throat
- Injection site bruising
These are described as commonly temporary. The doctor should be consulted immediately if a sore throat, headache, or another effect persists.
Precautions
- The doctor should be informed about heart, kidney, or liver issues
- Alcohol intake should be limited as much as possible
- The injection should not be stopped midway, as that can raise blood sugar levels
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical and healthcare products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it is a combination of insulin degludec and liraglutide used for the treatment of type 2 diabetes mellitus, alongside diet and exercise. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling describes it as injected under the skin, given by a doctor or nurse or self-injected using the technique they teach, used regularly at the prescribed dose and not stopped midway.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.